| Title |
β-TrCP Inhibition Reduces Prostate Cancer Cell Growth via Upregulation of the Aryl Hydrocarbon Receptor
|
|---|---|
| Published in |
PLOS ONE, February 2010
|
| DOI | 10.1371/journal.pone.0009060 |
| Pubmed ID | |
| Authors |
Udi Gluschnaider, Guy Hidas, Gady Cojocaru, Vladimir Yutkin, Yinon Ben-Neriah, Eli Pikarsky |
| Abstract |
Prostate cancer is a common and heterogeneous disease, where androgen receptor (AR) signaling plays a pivotal role in development and progression. The initial treatment for advanced prostate cancer is suppression of androgen signaling. Later on, essentially all patients develop an androgen independent stage which does not respond to anti hormonal treatment. Thus, alternative strategies targeting novel molecular mechanisms are required. beta-TrCP is an E3 ligase that targets various substrates essential for many aspects of tumorigenesis. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 39% |
| Student > Ph. D. Student | 6 | 16% |
| Student > Bachelor | 5 | 13% |
| Student > Master | 2 | 5% |
| Other | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 6 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 9 | 24% |
| Biochemistry, Genetics and Molecular Biology | 7 | 18% |
| Chemistry | 5 | 13% |
| Medicine and Dentistry | 4 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 8 | 21% |